Search clinical trials for: High risk of recurrence

Total 431814 results

The First Hospital of Jilin University
Geneplus-Beijing Co. Ltd.

Recruiting

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

Endometrial Cancer

China
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
Hospices Civils de Lyon
Exeliom Biosciences

Not yet recruiting

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients (LIVEDIFF)

Clostridioides Difficile Infection | Recurrent Infection

France
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Shanghai Municipal Hospital of Traditional Chinese...
Shanghai University of Traditional Chinese Medicine

Recruiting

IDUS in CBD Stone Recurrence High Risk Patients

Ultrasonography | Choledocholithiasis | Cholangiopancreatography, Endoscopic Retrograde

China
Chengdu CoenBiotech Co., Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Muscle Invasive Bladder Cancer

China
Medical College of Wisconsin

Recruiting

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence (PROTECT-PANC)

Pancreas Cancer

United States
Peking University First Hospital
Peking University First Hospital Miyun Hospital

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

Upper Urinary Tract Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma

China
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States
Fudan University

Recruiting

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence (IMPROVE)

Colorectal Cancer | Liver Metastases | Radiotherapy | Immunotherapy

China
Peking Union Medical College Hospital

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer

China
Gruppo Oncologico del Nord-Ovest

Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence (PURITY)

Cholangiocarcinoma | Biliary Tract Cancer

Italy
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Peking University People's Hospital

Recruiting

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Gastrointestinal Stromal Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Xian-Janssen Pharmaceutical Ltd.

Not yet recruiting

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) (ARES)

Prostate Cancer | Biochemical Recurrence | High Risk

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Pfizer

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

ACUTE LYMPHOBLASTIC LEUKEMIA

Italy, Spain, Belgium, Germany, Hungary, Switzerland, Norway, Austria, France, Czechia, Finland, Netherlands, Sweden, Israel, Poland, Denmark, Greece, Slovakia
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
Sichuan University

Recruiting

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Leukemia, Myeloid, Acute

China
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Ruijin Hospital

Recruiting

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Soft Tissue Sarcoma | Radiotherapy | Anlotinib | High Risk of Recurrence

China
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Wu Nan

Not yet recruiting

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

Non-Small Cell Lung Cancer
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Anhui Provincial Hospital
Henan Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; First...

Recruiting

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
Peking University People's Hospital

Recruiting

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Gastrointestinal Stromal Tumors | Minimal Residual Disease

China
Newish Technology (Beijing) Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Fudan University

Recruiting

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma

China
Second Affiliated Hospital, School of Medicine,...
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Resectable Esophageal Cancer

China
Andrew E. Place, MD
University of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaborators

Recruiting

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditions

United States
Fudan University

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

China
Chinese PLA General Hospital
Immunotech Applied Science Ltd.

Recruiting

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma (HCC)

China
Nationwide Children's Hospital
Exelixis

Recruiting

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Sarcoma | Neuroblastoma

United States
Xianhai Mao
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (ALTER-H006)

Hepatocellular Carcinoma | Adjuvant Therapy

China
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
Assistance Publique - Hôpitaux de Paris
Société de Dermatologie Française

Not yet recruiting

Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence (NAKIMEL)

Melanoma
Institute of Oncology Ljubljana

Recruiting

Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence (ICONA)

Locally Advanced Rectal Cancer

Slovenia
M.D. Anderson Cancer Center

Recruiting

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Serous Adenocarcinoma | Malignant Uterine Neoplasm | Endometrial Mucinous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Zhejiang University
Shandong Cancer Hospital and Institute; First Hospital of China Medical University and other collaborators

Recruiting

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma | Adjuvant Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

Breast Cancer

Korea, Republic of, United States, Australia, China, Ukraine, Spain, United Kingdom, Turkey, Mexico, Brazil, Austria, Belgium, Denmark, Germany, Greece, Russian Federation, Taiwan, France, Kenya, New Zealand, Portugal, Thailand, Rom... and more
Fudan University

Recruiting

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Cholangiocarcinoma, Intrahepatic

China

Search clinical trials for: High risk of recurrence

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations